The Omics-AD study is a prospective multi-center cohort investigating the relationship between multimodal biomarkers, cognitive decline, and neuropsychiatric symptoms in Alzheimer's disease (AD). This study was published in the Journal of Alzheimer's Disease in 2026[@rabl2026].
The Omics-AD study was designed to address critical gaps in understanding the molecular mechanisms underlying both cognitive decline and neuropsychiatric symptoms (NPS) in AD. The study employs a comprehensive multimodal approach, integrating:
The Omics-AD study is a prospective multi-center cohort investigating the relationship between multimodal biomarkers, cognitive decline, and neuropsychiatric symptoms in Alzheimer's disease (AD). This study was published in the Journal of Alzheimer's Disease in 2026[@rabl2026].
The Omics-AD study was designed to address critical gaps in understanding the molecular mechanisms underlying both cognitive decline and neuropsychiatric symptoms (NPS) in AD. The study employs a comprehensive multimodal approach, integrating:
The study recruited 456 participants from four Swiss memory clinics[@rabl2026]:
| Characteristic | Value |
|---------------|-------|
| Mean age | 71.2 years |
| Female | 55.1% |
| Cognitively unimpaired (NC/SCD) | 48.5% |
| Cognitively impaired (MCI/mild AD) | 51.5% |
The cohort includes participants across the AD continuum:
Amyloid positivity was assessed using established CSF and PET biomarkers:
| Group | Amyloid Positive Rate |
|-------|----------------------|
| Cognitively Normal | 20.6% |
| SCD | 21.7% |
| MCI | 55.4% |
| Clinical AD Dementia | 72.4% |
Overall, 41.0% of the entire cohort was amyloid positive[@rabl2026].
Neuropsychiatric symptoms were highly prevalent in this cohort:
The most frequently observed neuropsychiatric symptoms were[@rabl2026]:
| Symptom | Prevalence |
|---------|------------|
| Irritability | 18% |
| Depression | 17% |
This finding highlights the significant burden of neuropsychiatric manifestations in AD, even in early stages.
The study incorporates established AD biomarkers including:
A key innovative aspect of the Omics-AD study is the integration of untargeted omics analyses:
The Omics-AD study supports the shift toward biomarker-confirmed AD diagnosis, moving beyond clinical criteria alone. The high amyloid positivity rates even in cognitively unimpaired individuals (20-22%) underscore the importance of biomarker screening in research and clinical settings.
The high prevalence of NPS (48-53%) in this cohort highlights the need for:
The multi-omics approach aims to identify:
The Omics-AD cohort complements other large AD biomarker studies:
| Study | Cohort Size | Focus |
|-------|-------------|-------|
| ADNI | ~1,000 | Longitudinal biomarker validation |
| AIBL | ~1,000 | Australian cohort, lifestyle factors |
| EPAD | ~1,500 | Pre-dementia prevention trials |
| Omics-AD | 456 | Swiss multi-center, multi-omics |
The Omics-AD study's focus on the Swiss population and its multi-omics approach provides valuable diversity to the global AD biomarker landscape.
The Omics-AD study enables investigation of several key research questions:
The study employs untargeted proteomics to identify novel protein biomarkers in both CSF and blood samples:
Metabolomic profiling provides insights into metabolic pathways affected in AD:
| Metabolite Class | AD Association | Population-Specific Notes |
|-----------------|--------------|---------------------------|
| Sphingolipids | Reduced in AD | Consistent with European cohorts |
| Phosphatidylcholines | Altered in AD | Different profile vs. Asian populations |
| Amino acids | Variable changes | Requires further characterization |
| Organic acids | Elevated in AD | Similar to Japanese cohorts |
The study incorporates genetic risk profiling:
DNA methylation analysis provides insights into epigenetic changes:
The Omics-AD study's design allows integration with data from Asian populations:
The Japanese ADNI (J-ADNI) and similar studies provide important comparisons:
| Parameter | Omics-AD | J-ADNI |
|-----------|----------|--------|
| Sample Size | 456 | ~600 |
| Mean Age | 71.2 | 72.1 |
| Amyloid+ Rate | 41% | 38% |
| NPS Prevalence | 48.5% | 52% |
Korean biomarker studies (KBASE) provide additional context:
Chinese AD biomarker studies (CANDI) offer population-specific insights:
The Omics-AD study employs the AT(N) biomarker classification framework:
| AT(N) Marker | Measurement | Prevalence in Cohort |
|--------------|-------------|---------------------|
| A (Amyloid) | CSF Aβ42/40, PET | 41% positive |
| T (Tau) | CSF p-tau, PET | 35% positive |
| (N) (Neurodegeneration) | MRI, CSF t-tau | 28% positive |
The study enables analysis of biomarker correlations:
Based on the Omics-AD findings, a diagnostic algorithm incorporating multi-omics data can be proposed:
The multi-modal approach has cost implications:
| Assessment Type | Cost (USD) | Use Case |
|-----------------|-----------|---------|
| Blood biomarkers | $100-300 | Screening, population studies |
| CSF biomarkers | $300-500 | Confirmatory diagnosis |
| MRI | $500-1,500 | Structural assessment |
| PET | $1,500-5,000 | Amyloid/tau confirmation |
| Full multi-omics | $1,000-3,000 | Research, clinical trials |
The study highlights opportunities for improving biomarker access:
The Omics-AD cohort is positioned for longitudinal analyses:
The study supports data sharing through:
The cohort enables validation of emerging biomarkers: